Brian Mueller - 13 Jan 2023 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
EVP, Chief Financial Officer
Signature
/s/ Laura Randall Woodhead, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
13 Jan 2023
Net transactions value
-$128,500
Form type
4
Filing time
17 Jan 2023, 20:57:08 UTC
Previous filing
15 Dec 2022
Next filing
02 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $157,750 +2,500 +9% $63.10 30,246 13 Jan 2023 Direct F1
transaction BMRN Common Stock Sale $286,250 -2,500 -8.3% $114.50 27,746 13 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -2,500 -33% $0.000000 5,000 13 Jan 2023 Common Stock 2,500 $63.10 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on March 14, 2022.
F2 Reflects the number of options outstanding after the transactions from this specific stock option grant.